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Abstract
C17 was first described about ten years ago as a gene expressed in CD34+ cells. A more recent study has suggested a role
for C17 in chondrogenesis and development of cartilage. However, based on sequence analysis, we believe that C17 has
homology to IL-2 and hence we present the hypothesis that C17 is a cytokine possessing immune-regulatory properties. We
provide evidence that C17 is a secreted protein preferentially expressed in chondrocytes, hence in cartilage-rich tissues.
Systemic expression of C17 in vivo reduces disease in a collagen antibody-induced arthritis model in mice (CAIA). Joint
protection is evident by delayed disease onset, minimal edema, bone protection and absence of diverse histological
features of disease. Expression of genes typically associated with acute joint inflammation and erosion of cartilage or bone is
blunted in the presence of C17. Consistent with the observed reduction in bone erosion, we demonstrate reduced levels of
RANKL in the paws and sera of mice over-expressing C17. Administration of C17 at the peak of disease, however, had no
effect on disease progression, indicating that C17’s immune-regulatory activity must be most prominent prior to or at the
onset of severe joint inflammation. Based on this data we propose C17 as a cytokine that s contributes to immune
homeostasis systemically or in a tissue-specific manner in the joint.
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Introduction
C17 (Cytl1, C4orf4, Cytokine-like protein 1, Protein C17,
UNQ1942/PRO4425) was first mentioned in the literature as a
predicted secreted protein, the mRNA of which is expressed in
human bone marrow- and cord blood-derived CD34+, but not
CD342, cells [1]. Also, C17 reportedly is one of several genes for
which elevated mRNA expression was identified in pre-malignant
prostate stromal cells [2]. Recently, C17 was shown to promote
chondrocyte differentiation from murine mesenchymal stem cells
[3]. Consistent with the idea of a role for C17 in chondrocyte
biology, presence of C17 protein has been reported in human
cartilage explants [4]. However, overall, available information
about C17 is sparse.
Here, we present the hypothesis that C17 may be a previously
unrecognized member of the interleukin-2 (IL-2) cytokine family
and therefore may possess immune-regulatory properties. Based
on our hypothesis and the notion of C17’s role in cartilage
formation and regeneration, we decided to employ the technology
of hydrodynamic delivery [5], in order to test effects of C17 over-
expression in the context of acute joint inflammation in vivo.
Choice of the CAIA model of rheumatoid arthritis permitted us to
focus primarily on the acute inflammatory phase of arthritic
disease.
Our results demonstrate that C17 can significantly reduce acute
joint inflammation as evidenced by reduction of disease incidence,
clinical disease score, and diverse histological parameters. Further-
more, C17 blocks expression of several key inflammatory genes, as
well as expression of genes associated with bone and cartilage
destruction. Our results suggest that C17 contributes to mainte-
nance of immune homeostasis and support the idea of considering
complementation of existing arthritis therapies with C17.
Materials and Methods
Transient transfection and expression of C17 in 293 cells
Human or mouse C17 containing their respective native signal
sequences was cloned into the pTT5 expression vector to yield a
C-terminus dual tagged V5 peptide (GKPIPNPLLGLDST)/octa-
histidine fusion (V5H8) expression construct. C17-V5H8 was then
transfected into a 50 ml culture of 293Ebna cells at 1610
6 cells/
ml by mixing 50 ug plasmid DNA, 100 ug Polyethlenimine (PEI),
5 ml Opti-MEM Reduced Serum media and incubating for
15 min at RT. The PEI-DNA-cell mixture was shaken at 37 C,
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1 L Erlenmeyer Baffled Flask (Corning). Supernatant was col-
lected 72 hrs post transfection and concentrated ten-fold with
Amicon Ultra centrifugal Filters and buffer exchanged with PBS
using same filters. Cell pellets were harvested and lysed using 5 ml
of 1 M NaCl, 1 mM EDTA, 1% Triton and 10 mM Tris-HCl,
brought up to 50 ml with PBS and concentrated in the same
manner as the supernatant. The concentrated supernatant or
lysate was analyzed by Coomassie (Simply Blue) and Western blot,
followed by transfer onto nitrocellulose membrane. The blot was
blocked in 2.5% non-fat milk (Carnation) and 0.05% Tween/PBS
for 10 min. To detect C17-V5H8, a 1:3,333 dilution of 66His
mAb-HRP Conjugate (Clontech #631210) was added to the
blocking solution and the antibody was bound overnight at 4 C.
The blot was washed with a solution of 0.05% Tween/PBS and
was detected using Amersham ECL Western Blotting Detection
Reagent (GE Healthcare; Pittsburgh, PA).
Construction and production of GFP and C17-V5H8
minicircle vectors
GFP or full length murine C17-V5H8 was cloned into the
p2øC31.RSV.hAAT.bpA plasmid, kindly provided by Dr. Zhi-
Ying Chen (Stanford University, Stanford, CA). We modified the
vector and introduced unique 59 PmeI and 39 PacI restriction
sites to facilitate directional cloning of cDNA’s. We used PCR
amplification to place 59 PmeI and 39 PacI cloning sites on the
cDNA’s and ligate these with the modified minicircle producing
vector. GFP or C17-V5H8 minicircle DNA was produced fol-
lowing the methods described by Chen et al. [5] with some minor
modifications. For overnight cultures we inoculated 1 liter of
Terrific broth containing 100 ug/ml Ampicillin and incubated
18 hrs shaking at 270 rpm. We followed the minicircle produc-
tion method [6], precipitated cultures and stored at 280 C. We
used endotoxin free Qiagen megaprep kits for DNA purification,
with 120 ml volumes of solution P1, 2&3. Minicircle DNA was
eluted from the column; isopropanol was added and stored at
220 C. DNA was precipitated by spinning at 12 K, 309 at 4 C,
rinsed with 70% ethanol, air dried and resuspended in 1 ml of
endotoxin-free Tris EDTA. Minicircle DNA was dialized in Midi
MWCO 3.5 kDa tubes overnight against Tris EDTA. Purified
minicircle DNA was verified by restriction digestion and
sequencing.
Mice and in vivo hydrodynamic gene delivery
Male B10.RIII mice were purchased from The Jackson Labora-
tory and housed under sterile conditions at Merck Research Labs.
Hydrodynamic injections were performed under approved
IACUC protocol and as described [7]. Essentially mice were
injected in the tail vein with 2–3 mls Ringer’s solution (Baxter;
Deerfield, IL) containing 20 ug of minicircle DNA. The total
injection volume was equivalent to 10% of the mass of the animal.
Injections were performed rapidly, within 5–7 seconds using a
3 ml syringe fitted with a 27-guage needle.
Induction of arthritis
CAIA was induced in wild type 12–16 week old B10.RIII males
3–4 days after hydrodynamic injection with GFP or C17-V5H8
minicircle, as described above. The mice were administered an
intravenous injection of 4-clone arthrogenic monoclonal anti-
bodycocktail (Chondrex; Redmond, WA.) Animals were moni-
tored and scored daily thereafter for swelling and redness in the
paws using a 0–3 scoring system per paw (maximum score per
animal is 12): 0=normal; 1=mild redness or swelling in one digit
or joint; 2=moderate swelling or redness in multiple digits or
joints; 3=severe swelling or redness in all digits and throughout
the entire paw. The increase in thickness of the hind paw due
to edema was measured using a mechanical caliper (Mitutoyo,
USA).
Histopathological assessment of arthritic paws
Hind paws were dissected at the hairline and fixed in cold 10%
neutral buffered formalin for 2 days, followed by decalcification in
10% EDTA solution at 4 C for 7 days, then processed for paraf-
fin embedding. 5 micron sections were stained with H&E and
Safranin O. Histological scores for articular cartilage damage,
cortical bone erosion (0–3 scale) or for reactive synovium, leuko-
cyte infiltration, pannus formation, gestalt score (0–4 scale) were
assigned as follows: 0=normal, 1–3 or 1–4: increasing degree of
severity, depending on the parameter). Scoring parameters were
assigned by a pathologist who was blinded to the different
treatment groups. Two randomly selected sections were scored per
paw.
Immunohistochemistry
IHC was performed using a standardized staining protocol on
formalin-fixed, paraffin-embedded tissues using a monoclonal
antibody against C17-V5H8.
Micro-computed tomography (micro-CT) analysis
Formalin-fixed hind paws were briefly rinsed for 15 min with
cold running water prior to scanning. microCT imaging was
performed with GE eXplore Lotus micro-CT instrument. (GE
Healthcare, Piscataway, New Jersey). Images were acquired at
27 mm isotropic voxel size with 720 projections by 360 degree
scan, integration time of 2000 msec with three frames, photon
energy of 80 KeV and current of 450 uA. Acquisition time was
approximately 100 minutes per scan, followed by an hour of
projection correction and volume reconstruction. Maximum inten-
sity projection and 3D image rendering were generated through
original volumetric reconstructed images using Microview soft-
ware (GE Healthcare).
Serum analyses
Whole blood, collected at the end of the experiment by cardiac
puncture, was centrifuged in serum gel tubes (Sarstedt) for 15 min
at 4 C. Serum levels of C17-V5H8 were determined by ELISA.
Nunc MaxiSorp plates were coated overnight at 4 C with anti-V5
antibody (Invitrogen; Carlsbad, CA) in 50 mM sodium bicarbon-
ate buffer, pH 9.6. Plates were washed 3 times with 0.05%
Tween/PBS and blocked with 2% BSA, 0.5% Tween/PBS for
2 hrs at RT. Purified recombinant C17-V5H8 protein diluted in
normal mouse serum (Jackson ImmunoResearch; West Grove, PA)
was used as the standard. Serum from minicircle treated animals
were diluted in 2% BSA, 0.05% Tween/PBS, and incubated for
2 hrs at RT. After washing, HRP anti-His (R&D Systems;
Minneapolis, MN) was added for 1 hr. Plates were developed
using TMB Peroxidase EIA Substrate (Biorad; Hercules, CA) and
the color reaction was stopped with 1 M phosphoric acid. The OD
at 450 nm was assessed on a SpectrMax 340PC microplate reader
(Molecular Devices; Sunnyvale, CA) Serum levels of RANKL
(R&D Systems,) and COMP (Immunodiagnostics ) were deter-
mined using commercially available kits.
C17-V5H8 purification
Protein was purifed from cell culture supernatants using affinity
chromatography beads against the poly-histidine tag.
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Frozen tissues were homogenized using a polytron homogenizer
and processed for RNA isolation; qRT-PCR was performed as
described previously [8] [9].
Statistical analysis
The mean and SEM were determined using GraphPad Prism 4
software. Student’s t-test and Tukey’s test was used for statistical
analyses.
Results
C17 has first been mentioned in the scientific literature as a
gene expressed in CD34+ cells about ten years ago [1]; to date,
however, only quite limited information is available about its
function. Systematic structure-guided protein sequence analysis of
C17 reveals homology to the IL-2-related common gamma chain-
dependent cytokines (Fig. 1). In addition, the genomic organiza-
tion of exons and introns in the C17 gene locus, as well as the
positioning of exon fusion sites relative to the predicted C17
secondary structure elements, is similar to the arrangement found
for genes encoding other IL-2 cytokine family members. IL-2 and
its close relatives have prominent roles in immune regulation [10]
[11]. We therefore postulated that C17 may have the potential to
modulate immune responses.
To verify the hypothesis that C17 is a secreted protein, we
transfected HEK293T cells, a human embryonic kidney epithelial
cell line that is frequently used for production of secreted proteins
in the cellular supernatants after transient transfection, with a
plasmid encoding mouse or human C17. We have not tried other
cells or cell lines for expression of recombinant mouse or human
C17 in our studies. Both constructs included the full length cDNA
for C17 fused to two sequential C-terminal tags, V5H8. Western
blot analysis of the cellular lysates and supernatants demonstrated
C17 expression and secretion, respectively. The apparent mass of
both mouse and human C17 in the supernatants is larger than
expected (,26 kDa vs 18 kDa) and is somewhat higher in the
supernatants compared to the lysates suggesting that post-
translational modifications of the C17 polypeptide may occur
(Fig. 2). Consistent with these results, purified human C17-V5H8
has an apparent mass of approximately 26 kDa by SDS-PAGE
(Fig. 3A). Biochemical characterization of affinity-purified human
C17-V5H8 using size exclusion chromatography showed no evi-
dence of dimers or oligomers, matching what would be expected
for an IL-2-related cytokine (Fig. 3B).
In order to identify the most relevant sites of C17 expression
in vivo, we profiled a wide array of mouse tissues. While C17
mRNA is detectable in various tissues, highest levels of mRNA
were detected in cartilage-rich tissues such as trachea and joint
(Fig. 4A).
Figure 1. C17 is related to the family of common gamma chain-dependent cytokines. ClustalW multiple protein sequence alignment with
some manual adjustment. Sequences of human cytokines, structurally related to IL-2, were aligned. C17 is highlighted in purple. Blue sequence
denotes structure-confirmed alpha-helical secondary structure elements of respective cytokine (IL-2, PDB 2B5I; IL-4, PDB 1ITM; IL-13, PDB 1IKO; IL-15,
PDB 2PSM; IL-21, PDB 2QQP). Light blue background confirms amino acid residues providing contacts to the respective protein core, according to
afore listed structure data. Grey background denotes amino acid residues with predicted protein core contacts. Symbols *, :, . denote different levels
of amino acid similarity/identity. The arrow heads indicate two residues for predicted O-linked glycosylation that are conserved between human and
mouse C17.
doi:10.1371/journal.pone.0022256.g001
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an anti-C17 monoclonal antibody (mAb) for immunohistochem-
ical (IHC) staining (Fig. 4B). Our results expand on, and are
consistent with, the reports of C17 mRNA and protein expression
in cartilage [3] [4].
Next we sought to address the question if systemic over-
expression of C17 in vivo would result in development of
inflammation-associated pathology. For that purpose we applied
the technology of hydrodynamic delivery of minicircle DNA. This
method permits immediate and sustained hepatic transgene
expression in vivo [5]. In lack of suitable antibody reagents for
tracking of C17 protein in serum, we chose to use a minicircle
encoding mouse C17 with the dual C-terminal tags, V5H8. With
this tool, serum levels of the dual-tagged protein could be
determined using a sandwich ELISA approach with mAbs recog-
nizing the tags. Two control groups were used in this experiment:
a group that was not injected, and a group that received minicircle
encoding GFP. The mice were sacrificed after 35 days, and
hepatic expression of C17 mRNA was verified after take down
(Fig. 5A) Furthermore, IHC staining using an anti-C17 mAb
confirmed hepatic C17 protein expression in C17-treated, but not
GFP-treated mice. C17 staining was not observed in liver sections
stained with an isotype control mAb (not shown). We also
confirmed the presence of C17-V5H8 in the serum by ELISA
(Fig. 5C). Necropsies were performed on the sacrificed animals
and the following organs harvested: heart, aorta, lung, brain,
thymus, liver, spleen, pancreas, kidney, stomach, small intestine,
large intestine, cecum, tibia, sternum, trachea, cervical lymph
node, skin. Tissues were embedded, sectioned and stained with
H&E for histological analysis. No differences between the three
groups were observed in systematic histological examination of
sections generated from afore mentioned tissues (not shown). A
panel of cytokines and chemokines was measured in the sera using
a multiplex ELISA assay but no differences were observed (not
shown). Mice of all groups gained weight in a comparable fashion
during the five week experimental period (data not shown). Hence,
no features suggesting a C17-dependent inflammatory response
were observed in this experiment.
As C17 is expressed in the joint and does not appear to act as a
pro-inflammatory factor, we chose to investigate the impact of
C17 expression in the context of CAIA, an in vivo model of acute
joint inflammation and joint erosion. Three groups of mice were
included in this study: one group received GFP minicircle on day
23 and arthrogenic cocktail on day 0, one group received C17-
V5H8 minicircle on day 23 and arthrogenic cocktail on day 0,
one group was kept naı ¨ve (ie, no minicircle or arthrogen). This
timing was chosen because the murine liver appears to fully
recover from hydrodynamic delivery within three days and no
evidence of hepatic damage is detectable in the serum or by
histology at this time point (data not shown). Typically, 100%
disease incidence is reached at day 3–4 in this model, which was
observed for the GFP group. Likewise, animals injected with
Ringer’s solution only developed disease after receiving the Ab
cocktail to a similar extent and with 100% incidence (data not
shown). In contrast, the C17 group had a delayed incidence with
only 60% incidence on day 4 and 100% reached at day 8 (Fig. 6A).
By day 7, the disease had reached its peak in the GFP treated
mice, which demonstrated a mean clinical disease score of
Figure 2. Human and mouse C17 are secreted proteins in vitro.
HEK293 cells were transfected with eukaryotic expression vectors
encoding C-terminally dual-tagged (V5H8 tags) human and mouse C17
protein. The tags were fused to the 39 end of the full cDNA, retaining
the natural N-terminal signal peptide and complete mature portion of
C17. Supernatants and lysates were harvested and adjusted by volumes
to permit direct comparison of protein quantities by Western blot.
Proteins were separated by SDS-PAGE and visualized with an anti-poly
His antibody. The same blot is shown twice with short (top) and long
(bottom) exposure.
doi:10.1371/journal.pone.0022256.g002
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261.0. Clinical disease score was significantly reduced in C17-
treated mice compared to GFP controls (p=0.007), whereas the
naı ¨ve mice had no clinical signs of disease, as expected (Fig. 6B).
The degree of edema in the hind feet of mice was quantified on
day eleven using a caliper. While C17 treated mice essentially
showed no or only minimal swelling of the hind paws, GFP treated
mice displayed significant edema (Fig. 6C). To confirm mRNA
and protein expression for C17 during our study, samples of liver
and serum were analyzed, respectively (Fig. 6D, 6E).
Upon sacrifice of the experimental animals, paws were
embedded, sectioned and stained with H&E and then scored in
a blinded fashion according to different histological criteria. Paws
from GFP-treated animals showed features of severe arthritis,
whereas paws from C17-treated animals were largely protected
(Fig. 7A, 7B). Representative sections that were stained with H&E
and with the cartilage-specific dye SafraninO underscore the
protective effect of C17 on the joints (Fig. 7A). Paws were also
harvested for micro-CT analysis. Paws from GFP control-treated
mice showed considerable alterations in cortical bone density,
with most apparent bone loss in the knuckle region. In contrast,
paws from C17-treated animals were similar to naı ¨ve paws
with minimal, if any, changes in bone structural integrity
(Fig. 7C).
As an additional level of analysis we performed gene expression
profiling of the hind paws. We focused on some cytokine genes
implicated with joint inflammation (Fig. 8A), and studied genes
that are associated with pathologic tissue remodeling in the joint
and/or bone (Fig. 8B). C17 dramatically reduced gene expression
of IL-1b and IL-6, but had little impact on TNFa, IFNg and IL-17
(Fig. 8A). Generally, in the presence of C17, several other genes,
typically associated with inflammation and pathological tissue
remodeling in the joint, are kept to normal expression levels found
in un-manipulated animals (Fig. 8B). This pattern of gene expres-
sion in the paw is consistent with the clinical disease scores and the
results obtained from histological examination. Intriguingly,
several inflammatory genes were trending to reduced expression
with C17, even if paws matched for maximal clinical disease score
were analyzed (Fig. 8C). C17 mRNA in the paw was reduced in
mice receiving arthrogen compared to naı ¨ve mice, however, no
significant difference occurred in GFP-treated compared to C17-
treated animals (Fig. 8D).
Figure 3. C17 protein is monomeric. (A) Recombinant purified human C17-V5H8 was analyzed by SDS-PAGE under reducing (1) and non-
reducing (2) loading conditions and subsequent Coomassi staining. A protein marker is shown in the right column (3). (B) Baseline drift-corrected
A280 nm elution profile of size exclusion chromatography after loading affinity-purified human C17-V5H8. Retention times of marker proteins (in kDa)
are indicated above.
doi:10.1371/journal.pone.0022256.g003
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serum biomarkers used for assessing bone and cartilage destruc-
tion, respectively. Serum levels of both markers were measured in
the mice at the time of euthanasia: COMP serum levels were
similar between naı ¨ve, and GFP and C17 treated groups receiving
arthrogen. RANKL was elevated in the mice that had received the
arthrogen compared to naive, and the concentration was lower in
C17-treated compared to GFP-treated mice (Fig. 9).
To rule out the possibility that the V5H8-peptide tag attached
to C17 was responsible for joint protection observed with C17, we
performed an experiment in which, besides the C17-V5H8 and
GFP, two control groups were included: untagged C17, and
V5H8-tagged IL-22BP. As described above, minicircle vectors
were administered at day 23, and the mice were challenged with
the arthrogenic cocktail on day 0 and then followed for 11 days.
Similar disease incidence and comparably mild joint swelling was
observed in both groups, untagged C17 and C17-V5H8. GFP-
treated mice developed maximal disease incidence and higher
clinical scores than mice treated with either untagged C17 or C17-
V5H8. However, mice receiving V5H8-tagged IL-22BP were
Figure 4. C17 mRNA and protein are expressed in cartilage-rich tissues and chondrocytes, respectively. (A) A variety of tissues were
harvested and pooled from three C57BL/6 mice and then analyzed for C17 mRNA expression using qPCR (n.d., not detected). (B)
Immunohistochemical staining for C17 on mouse sternal cartilage, using a mAb anti-C17, demonstrates protein expression by chondrocytes.
Scale bars represent 0.1 mm.
doi:10.1371/journal.pone.0022256.g004
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provided no evidence for an anti-inflammatory effect caused by
the V5H8 peptide tag.
The studies described above provide evidence for a potent anti-
inflammatory and joint-protective effect of C17 if administered in
a preventive setting. To investigate if C17 affects established joint
inflammation we tested C17 over-expression in a therapeutic
experiment. CAIA was induced on day 0 and minicircle vector
encoding C17 or GFP were administered at day 5 when clinical
disease symptoms are evident. Progression of clinical disease
beyond day 5 was not different between GFP- and C17-treated
groups (Fig. 11A). Paws were harvested from euthanized animals
at day 17, and H&E stained sections were assessed according to
disease severity by histology gestalt score of arthritic joint disease,
but no differences between groups were observed (Fig. 11B).
Systemic exposure to C17 was verified by confirming C17-V5H8
serum levels (Fig. 11C). Hence, this experiment did not provide
evidence for a joint-protective effect of C17 when administered in
the context of severe joint inflammation in established CAIA.
Discussion
We decided to take a bioinformatics-based approach in an
attempt to link C17 to a protein family and thus generate an initial
working hypothesis. Two previous articles had predicted C17
as a secreted cytokine-like protein with alpha-helical secondary
Figure 5. Sustained over-expression of C17 does not result in an inflammatory response in vivo. Age-and sex-matched mice received a
hydrodynamic injection of C17 or GFP (control) minicircle, or were kept naı ¨ve. (A) After five weeks, animals were euthanized and hepatic over-
expression of C17 mRNA was verified. In addition, (B) hepatic expression of C17 protein was confirmed by IHC using an anti-C17 mAb (top row) or
isotype control Ab (bottom row); arrowheads highlight areas of positive C17 staining in C17-transfected, but not naı ¨ve or GFP-transfected liver;
images were taken at 206magnification. (C) Systemic exposure to C17 was verified by measuring serum levels of tagged C17 protein. Data shown
represent a typical result from at least two independent experiments with five or more animals per group.
doi:10.1371/journal.pone.0022256.g005
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Several families of cytokines show structural features that involve
alpha-helical bundle topologies, including IL-10-related cytokines,
type I Interferons, common beta chain (CD131)-dependent
cytokines, common gamma chain (CD132)-dependent cytokines,
IL-6/12 related cytokines, and others [12][13][14]. Careful
sequence analysis unveiled a close relationship of C17 to the IL-
2-related, common gamma chain (CD132)-dependent, cytokines
(Fig. 1).
Cytokines - by definition - are released from their respec-
tive producer cells as molecular messengers facilitating cell-cell
communication. Hence, we set out to confirm that C17 is in fact a
secreted molecule. Recombinant forms of both human and mouse
C17 were detected in the supernatants after transfection of 293
cells. Of note, the secreted forms of both mouse and human C17
appear larger than the forms detected in the corresponding cell
lysates (Fig. 2). This suggests post-translational modification of
C17. The most common post-translational modifications intro-
duced to secreted proteins are enzymatic glycosylations, either
N- or O-linked, with the former being observed frequently among
cytokine molecules. N-linked glycosylation can occur on aspara-
gine residues which are part of the consensus motif NXS/T.
O-linked glycosylation can occur on either serine or threonine
residues; however due to a lack of a consensus motif, sites for
O-linked glycosylation are difficult to predict. As protein sequences
for both human and mouse C17 lack the consensus motif NXS/T,
we propose that C17 undergoes O-linked glycosylation prior to its
release. Interestingly, two threonine residues, one close to the
N-terminus of the processed C17 and one close to its C-terminus,
are conserved between human and mouse C17 protein sequences
and are predicted sites for O-linked glycosylation (compare Fig. 1).
Our results are in agreement with a report showing expression and
secretion of mouse C17 in murine rib chondrocytes [3] (Fig. 4B),
and of human C17 in transfected cells [1] (Fig. 2).
Biochemical analysis of affinity-purified C17 showed no evi-
dence for formation of covalent or non-covalent oligomers (fig. 3A).
Unlike e.g. IL-10, which requires formation of a homodimer for
efficient receptor engagement, no evidence for oligomerization of
common gamma chain (CD132)-dependent cytokines is reported
in the literature. Likewise, our size exclusion chromatography data
of purified C17V5H8 does not suggest formation of oligomers
(Fig. 3B). Therefore, our findings are compatible with the hy-
pothesis of C17 being an IL-2-related factor.
Based on this, we attempted to match C17 to various common
gamma chain- related hematopoietic cytokine receptors employing
biochemical methods, but no reproducible match could be
identified (data not shown). Consequently, the cell surface re-
ceptor(s) for C17 are presently unknown and will be subject to
future research.
We chose the method of hydrodynamic delivery of C17
minicircle in an effort to investigate the effects of C17 over-
expression in vivo. Using this approach with minicircles encoding
pro-inflammatory cytokines, e.g. IL-17, we have observed several
key features of systemic inflammation including weight loss,
increased blood leukocyte counts, tissue infiltration of activated
lymphocytes and/or granulocytes, and increased systemic levels of
Figure 6. C17 over-expression protects mice from collagen
antibody-induced arthritis. Age-matched male B10.RIII mice re-
ceived a hydrodynamic injection of GFP or C17 minicircle DNA in
Ringer’s solution. Three days later mice received a single dose of the 4-
clone arthrogenic mAb cocktail (3 mg) to induce CAIA (day 0), mice
were followed for eleven days and then euthanized. (A) Incidence of
disease and (B) mean clinical disease scores 6 SEM are shown.
Thickness of both hind footpads from each animal was measured with a
mechanical caliper at the time of euthanasia (C). Quantitative RT-PCR
was performed on liver tissues to verify hepatic expression of C17
mRNA (D), and protein levels in the serum were measured by ELISA (E).
Data shown here are representative of at least three independent
experiments with at least five animals per group.
doi:10.1371/journal.pone.0022256.g006
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in vivo over-expression of C17 for a five week period could be
confirmed by measuring C17 the serum, none of the above
features were recognized (Fig. 5). Of course, we have to formally
consider the possibility that hepatocytes in this study may express a
modified form of C17 and that therefore no overt effects were
evident. In light of the data described in the CAIA model,
however, such scenario appears unlikely.
Hence, we concluded that C17 does not act as pro-
inflammatory mediator in vivo, but instead may possess immune-
regulatory properties. An alternative interpretation of afore
mentioned findings may be that C17 target cells require
inflammation-associated signals to become sensitized to efficient
C17 signaling. Therefore, C17 may have limited activity under
homeostatic conditions. Owing this possibility, we selected a
model of acute joint inflammation, CAIA, in which to test the
effects of C17 over-expression.
Remarkably, expression of C17 resulted in delayed disease
onset, minimized edema and arthritis histopathology score, bone
protection, and reduced expression of many inflammation-asso-
ciated markers (Fig. 6, Fig. 7, Fig. 8). In fact, according to most
parameters, C17-treated mice that did receive the CAIA challenge
were indistinguishable from age- and gender-matched naı ¨ve mice
(Fig. 6, Fig. 7, Fig. 8). Considering the recent report that C17
supports chondrogenesis of mesenchymal stem cells [3], some level
of C17-mediated cartilage protection in this model may be
Figure 7. Bone erosion and histological parameters of arthritis are reduced in mice over-expressing C17. One hind paw per animal was
harvested at the time of euthanasia and was analyzed by micro-CT and subsequent histology. (A) Representative histology images from individual
hind paws are shown either stained with H&E (top row) or stained with Safranin O (bottom row). Images were taken at 106magnification. (B) Scoring
of disease severity according to diverse histological parameters. (C) Representive micro-CT scans are shown. Red box highlights prominent joint
erosion in paw of GFP treated mouse. Similar data were generated in at least three independent experiments with at least five animals per group.
doi:10.1371/journal.pone.0022256.g007
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protection on a broader scale, including suppression of inflam-
matory infiltrates, abrogation of pathological synovial reactivity,
suppression of pannus formation, and protection of cortical bone.
This indicates that C17 may elicit immune regulatory activity
acting through cells other than chondrocytes and/or that C17 is
capable of instructing chondrocytes to express a set of genes
critical for control of local inflammation and joint homeostasis.
At the time of euthanasia, gene expression of a variety of
markers associated with arthritic pathology was measured in the
paws. Expression of IL-1b and IL-6 mRNA was significantly
elevated in the paws of GFP control mice and reduced to
Figure 8. Reduced expression of inflammatory markers and genes associated with joint destruction in paws of C17-treated animals.
One hind paw per animal was harvested at the time of euthanasia and quantitative RT-PCR was performed to measure mRNA levels of cytokines
associated with joint inflammation (A), and genes associated with joint remodeling and arthritic tissue destruction (B). (C) mRNA expression of
selected genes from paws with severe swelling and matched clinical disease score 3. (D) C17 expression in paws from naı ¨ve animals and animals that
received arthrogen with GFP control or C17 minicircle. Values from naı ¨ve animals are shown as filled triangles, from GFP mice as filled squares, from
C17 mice as open circles, throughout the figure. Not significant: ns; p,0.05: *; p,0.01: **. Similar data were obtained in at least two independent
experiments with five or more mice per group.
doi:10.1371/journal.pone.0022256.g008
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was not different between GFP- and C17-treated animals.
Unexpectedly, both groups receiving minicircle showed reduced
TNFa mRNA relative to the naı ¨ve controls (Fig. 8A). These
findings are in agreement with a previous study that reported
sustained increase of IL-1b and IL-6 in this model; however,
TNFa expression did not seem to be linked to disease progression
[15]. IFNg and IL-17 levels were not different between groups
(fig. 8A). As activated T cells are a dominant source for both IFNg
and IL-17 and the CAIA model does not involve T cell priming,
this result is perhaps to be expected.
Several markers of bone and cartilage remodeling were also
analyzed. Expression of RANKL was increased in paws from GFP
control mice, whereas in the presence of C17 protein, RANKL
was reduced to levels observed in naı ¨ve animals (Fig. 8B). Receptor
activator of nuclear factor kappa B (RANK) was not differentially
expressed between groups and osteoprotegerin (OPG), the
endogenous antagonist of RANK/RANKL interactions, was
reduced in GFP-treated mice (Fig. 8B). As the RANK/RANKL
pathway is critical to support maturation and activity of
osteoclasts, this pattern of gene expression is consistent with the
Figure 9. SerumlevelsofRANKLarereducedinC17treatedmice.
At the time of euthanasia, serum was harvested from mice and analyzed
for protein levels of the cartilage damage marker, COMP,and the marker of
bone destruction, RANKL. Comparable results were obtained in at least
two independent experiments withfive or more mice per group.Only sera
of mice that had analyte levels above the manufacturer’s recommended
sensitivity level of the respective assays are shown in the figure.
doi:10.1371/journal.pone.0022256.g009
Figure 10. V5H8-peptide tag is not sufficient for protection from CAIA. Mice were injected with minicircle vector encoding GFP, V5H8-
tagged IL-22BP, V5H8-tagged C17-V5H8,or untagged C17, on day 23. Artherogenic Ab cocktail was administered on day 0 and animals(n=4–5/
group) were monitored and scored daily relating to (A) disease incidence, and (B) clinical disease score. (C) Hind paw thickness was measured with a
caliper on days 0 and 11, ***: p,0.001. (D) Presence of V5H8-tagged proteins in serum was verified on day 11; n.d., not detected.
doi:10.1371/journal.pone.0022256.g010
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Fig. 7). In addition, expression of tartrate resistance acid
phosphatase 5 (ACP-5/TRAP), a marker of osteoclast activity,
was also significantly elevated in paws from GFP control animals
but returned to base line in the presence of C17 (Fig. 8B).
Osteoclast differentiation is supported by bone-morphogenic
protein (BMP4) [16]. Our data shows significant up-regulation
of BMP4 mRNA in paws from GFP-treated control mice, but not
in C17-treated mice (Fig. 8B). Again, this finding supports the
conclusion of minimized osteoclast activity in the presence of C17.
COMP, matrix-metalloproteinase 1 (MMP-1), a disintegrin and
metalloproteinase with thrombospondin motifs 5 (ADAMTS5) are
expressed by chondrocytes and are genes critically involved in
cartilage remodeling and repair. As a marker for cartilage turn-
over, increases in COMP expression are indicative of increased
cartilage remodeling. COMP expression is reduced in C17-treated
animals (Fig. 8B). In mice, the aggrecanase ADAMTS5 is a potent
mediator of cartilage destruction, as ADAMTS5 deficiency results
in significant protection against cartilage erosion during experi-
mental arthritis (Fig. 8B) [17][18]. MMP-1 expression is also
significantly elevated in GFP-treated mice but similar between
naı ¨ve and C17-treated animals (Fig. 8B). MMP-1 expression by
arthritic synovial fibroblasts can be triggered through IL-1b [19].
As we did observe elevated IL-1b levels, it is perhaps to be
expected that MMP-1 expression is also elevated in the GFP group
but not the C17 group.
Elevated expression of aggrecan (AGC1) and type I collagen
(COL1A1), both of which are key components of articular
cartilage, is indicative of cartilage remodeling. Again, consistent
with increased cartilage turnover, expression of both genes is
elevated in the GFP-treated but not C17-treated or naı ¨ve animals
(Fig. 8B). Taken together, these gene expression profiles demon-
strate increased articular cartilage remodeling and repair activity
in this model, as expected, and, furthermore, support the notion
that C17 can be protective against inflammation-associated
cartilage breakdown in the joint.
When paws were matched for maximal clinical disease score
(score 3), expression of arthritis-associated genes showed a
consistent trend towards reduction in the presence of C17 with a
significant reduction observed for IL-6 (Fig. 8C). This indicates
that despite comparable clinical disease, C17 may still exert a
joint-protective effect. C17 mRNA is reduced in joints of mice
treated with arthrogen and the minicircle vector (Fig. 8D). Our
data do not permit a conclusion of whether or not the observed
reduction in C17 expression is a result of administration of the
arthrogen and/or of the minicircle. However, GFP-treated mice
trended towards reduced C17 mRNA, which may be explained by
prominent cartilage destruction in those animals compared to
C17-treated mice (compare to Fig. 7B).
However, C17 therapy had no effect on established CAIA.
When administered on day 5 of the model clinical disease scores
remained largely unchanged with GFP control, but also with C17
treatment (Fig. 11A). After animal sacrifice on day 17, gross
histologic examination revealed no differences between groups:
mice from both treatment groups showed inflammatory joint
infiltrates, bone/cartilage destruction, and reactive synovia,
resulting in similar histology gestalt scores (Fig. 11B).
These findings may be interpreted that C17 predominantly acts
prior to, or at the very onset of, CAIA and increases the activation
threshold for effector cells and/or alters their migration patterns.
An alternative explanation could be that the robust and rapid
inflammation triggered following delivery of the arthrogenic
cocktail, may be too dominant to be overcome once disease is
established.
Figure 11. C17 over-expression does not modulate established
arthritis. CAIA was induced in male B10.RIII mice with a single dose of
4-clone arthrogen on day 0, followed by hydrodynamic injection of GFP
or C17-V5H8 minicircle on day 5 when mice had developed prominent
paw inflammation. Mice were further monitored and euthanized at 17
days after initial disease induction. (A) The mean clinical disease scores
including SEM are shown. (B) Histology gestalt scores were assigned to
H&E-stained hind paws for GFP- and C17-treated animals. (C) Serum
expression of C17 was verified. Data shown represent a typical result
from at least two independent experiments with five or more animals
per group.
doi:10.1371/journal.pone.0022256.g011
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joint protection in a preventive setting but no protective effect was
observed therapeutically. Whether perhaps C17 administration
possesses therapeutic efficacy in milder or phenotypically different
forms of experimental arthritis will have to be determined by
future studies.
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